Growth retardation. Cachexia
Conditions
Interventions
Intervention 1: The first group was given Cyproheptadine syrup with dose 0.1 mg/kg/dose TDS orally for 2 months. Intervention 2: The second group was given Placebo with dose 0.1 mg/kg/dose TDS orally
Treatment - Drugs
The first group was given Cyproheptadine syrup with dose 0.1 mg/kg/dose TDS orally for 2 months.
The second group was given Placebo with dose 0.1 mg/kg/dose TDS orally for 2 months.
Sponsors
Zanjan University of Medical Science
Eligibility
Sex/Gender
All
Age
2 Years to 10 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria include: all children aged 2 to 10 years with a weight below the 50th percentile; Children whose parents have given consent to participate in the study. Exclusion criteria include: children with underlying organic condition (gastrointestinal, cardiovascular, respiratory, renal and nervous systems) causing growth failure; inappropriate use of medicines; discourage children from study; did not return for follow-up; occurs severe disease and side effects of medication.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight gain. Timepoint: Every month up to 2 months, 2 months after treatment. Method of measurement: Weighing the patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| Increase Height. Timepoint: Every month up to 2 months, 2 months after treatment. Method of measurement: height measurements.;Side Effects and complication. Timepoint: Every month up to 2 months, 2 months after treatment. Method of measurement: History and physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKambiz Eftekhari
Zanjan University of Medical Science
Outcome results
None listed